TransMedics Group Inc (TMDX) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

Total Assets Chart for TransMedics Group Inc

TransMedics Group Inc (TMDX) total assets for FY2025 were USD 1.1B, a 32.9% change from FY2024. TransMedics Group Inc's total assets grew from USD 14.9M in 2006 to USD 1.1B in 2025 (7068.4% over 19 years). Total assets compound annual growth rate: 5-year CAGR of 47.7%, 10-year CAGR of 53.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$2.45B
Implied Share Price
$70.74
Enterprise Value
$4.08B
Revenue (TTM)
$668.47M
EBITDA
$115.63M
Profit Margin
22.69%
Trailing P/E
18.33
Forward P/E
52.36
Price/Book (MRQ)
12.44
Price/Sales (TTM)
3.67
EV/EBITDA
36.40
EV/Revenue
7.67
Dividend Yield
—
Book Value
$14.96
Free Cash Flow (FY2025)
$133.59M
Free Cash Flow Yield
5.45%

Snapshot as of 25th October 2026 — not point-in-time controlled, may lag the live market by a few days.